Key result
Azimilide maintained its class III effect during beta-adrenergic stimulation, prolonging action potential duration by 8.7 ms versus a 2.6 ms shortening with isoproterenol alone (P=0.0051).
Why the study?
Does azimilide maintain its class III antiarrhythmic electrophysiologic effects in the presence of beta-adrenergic stimulation with isoproterenol in humans?
RCT (n=13)
Single-blind
randomized
Does azimilide maintain its class III antiarrhythmic electrophysiologic effects in the presence of beta-adrenergic stimulation with isoproterenol in humans?
Absolute Event Rate: 8.7% vs -2.6%
p-value: p=0.0051
Azimilide maintains its class III electrophysiologic effects (prolonging action potential duration and refractory period) even under beta-adrenergic stimulation with isoproterenol, likely due to its combined IKr and IKs blockade.
No takes yet. Share an insight, caveat, or question.
Azimilide may warrant consideration in sympathetic-driven arrhythmias; extends class III efficacy data to beta-stimulated conditions in humans.
Dorian et al. (2002) reported an RCT. Azimilide vs. Isoproterenol alone was evaluated on Monophasic action potential duration at 90% repolarization (p=0.0051). Azimilide maintained its class III effect during beta-adrenergic stimulation, prolonging action potential duration by 8.7 ms versus a 2.6 ms shortening with isoproterenol alone (P=0.0051).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: